News | June 05, 2024
AstraZeneca completes acquisition of Fusion Pharmaceuticals
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Subscribe To Our Newsletter & Stay Updated
